News
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...
3d
Flow Space on MSNSemaglutide Is Not the Best GLP-1 Drug You Can Take for Losing Weight FastSemaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
13h
News-Medical.Net on MSNHigher protein intake may help prevent muscle loss in semaglutide usersWomen and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help prevent muscle loss in these patients, according to a small ...
The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...
What is Ozempic teeth? Here is what you need to know about how the weight loss drug Ozempic may be impacting your health.
Bariatric Surgery vs. Weight-Loss Drugs: What Science Says About Effective Weight Loss with Diabetes
Struggling to lose weight with diabetes? Find out what science says about bariatric surgery vs. weight-loss drugs—and which ...
The longer weight loss GLP-1 drugs like Ozempic and Wegovy have been on the market, the more side effects people are ...
There’s no such thing as "natural Ozempic." While supplements like psyllium, berberine, and glucomannan are paraded as ...
Once-weekly cagrilintide–semaglutide combination therapy produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving ≥20% loss and strong cardiometabolic benefits ...
MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results